These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 26997015

  • 1. Preparation & in vitro evaluation of ⁹⁰Y-DOTA-rituximab.
    Kameswaran M, Pandey U, Dash A, Samuel G, Venkatesh M.
    Indian J Med Res; 2016 Jan; 143(1):57-65. PubMed ID: 26997015
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study.
    Forrer F, Chen J, Fani M, Powell P, Lohri A, Müller-Brand J, Moldenhauer G, Maecke HR.
    Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1443-52. PubMed ID: 19350237
    [Abstract] [Full Text] [Related]

  • 8. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM.
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Standardization of Procedures for the Preparation of (177)Lu- and (90)Y-labeled DOTA-Rituximab Based on the Freeze-dried Kit Formulation.
    Wojdowska W, Karczmarczyk U, Maurin M, Garnuszek P, Mikołajczak R.
    Curr Radiopharm; 2015 Jan; 8(1):62-8. PubMed ID: 25506704
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy.
    Dahle J, Borrebaek J, Melhus KB, Bruland OS, Salberg G, Olsen DR, Larsen RH.
    Nucl Med Biol; 2006 Feb; 33(2):271-9. PubMed ID: 16546683
    [Abstract] [Full Text] [Related]

  • 14. Technetium-99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma.
    Camacho X, Machado CL, García MF, Gambini JP, Banchero A, Fernández M, Oddone N, Bertolini Zanatta D, Rosal C, Buchpiguel CA, Chammas R, Riva E, Cabral P.
    Oncology; 2017 Feb; 92(4):229-242. PubMed ID: 28196364
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. ⁹⁹mTc carbonyl DTPA-rituximab: preparation and preliminary bioevaluation.
    Pandey U, Kameswaran M, Dev Sarma H, Samuel G.
    Appl Radiat Isot; 2014 Apr; 86():52-6. PubMed ID: 24486518
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Physicochemical Evaluation of Lyophilized Formulation of p-SCN-Bn-DOTA- and p-SCN-Bn-DTPA-rituximab for NHL Radio Immunotherapy.
    Ackova DG, Smilkov K, Janevik-Ivanovska E.
    Iran J Pharm Res; 2016 Apr; 15(3):295-302. PubMed ID: 27980563
    [Abstract] [Full Text] [Related]

  • 19. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
    Weber T, Bötticher B, Mier W, Sauter M, Krämer S, Leotta K, Keller A, Schlegelmilch A, Grosse-Hovest L, Jäger D, Haberkorn U, Arndt MA, Krauss J.
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366
    [Abstract] [Full Text] [Related]

  • 20. (99m)Tc-rituximab radiolabelled by photo-activation: a new non-Hodgkin's lymphoma imaging agent.
    Stopar TG, Mlinaric-Rascan I, Fettich J, Hojker S, Mather SJ.
    Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):53-9. PubMed ID: 16172899
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.